Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease
Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways
but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study …
but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study …
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature aging, 2024 - nature.com
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Alzheimer disease pathology and the cerebrospinal fluid proteome
Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …
A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …
pathophysiological changes that develop years before the onset of clinical symptoms. These …
Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery
Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life
A diverse set of biological processes have been implicated in the pathophysiology of
Alzheimer's disease (AD) and related dementias. However, there is limited understanding of …
Alzheimer's disease (AD) and related dementias. However, there is limited understanding of …
Alzheimer's disease: biomarkers in the genome, blood, and cerebrospinal fluid
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that slowly destroys
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 …
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 …
Biomarkers in sporadic and familial Alzheimer's disease
S Lista, SE O'Bryant, K Blennow… - Journal of …, 2015 - content.iospress.com
Most forms of Alzheimer's disease (AD) are sporadic (sAD) or inherited in a non-Mendelian
fashion, and less than 1% of cases are autosomal-dominant. Forms of sAD do not exhibit …
fashion, and less than 1% of cases are autosomal-dominant. Forms of sAD do not exhibit …
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease
To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …